Публикации Лаборатории Фармакодинамики и Фармакокинетики

  1.  Алиева К.Н., Фирсов А.А. Новое в фармакодинамике противобактериальных средств на 28-м конгрессе ECCMID. Эффективная фармакотерапия. Урология и нефрология. 2019; № 1, стр. 4-9. DOI: 10.33978/2307-3586-2019-15-1-16-21.

  2. Golikova M. V., Strukova E. N., Portnoy Y. A., Dovzhenko S. A., Kobrin M. B., Zinner S. H., Firsov A. A. Resistance studies with Streptococcus pneumoniae using an in vitro dynamic model: amoxicillin versus azithromycin at clinical exposures. J Chemother. 2019, 31:252-260. DOI: 10.1080/1120009X.2019.1623361.

  3. Golikova M. V., Strukova E. N., Portnoy Y. A., Dovzhenko S. A., Kobrin M. B., Zinner S. H., Firsov A. A. A novel parameter to predict the effects of antibiotic combinations on the development of Staphylococcus aureus resistance: in vitro model studies at subtherapeutic daptomycin and rifampicin exposures. J Chemother. 2019, 31(6):320-328. DOI: 10.1080/1120009X.2019.1640924.

  4. Golikova M. V., Strukova E. N., Portnoy Y. A., Zinner S. H., Firsov A. A. Predicting the antistaphylococcal effects of daptomycin–rifampicin combinations in an in vitro dynamic model. J. Antibiotics. 2019. Doi: 10.1038/s41429-019-0249-x.

  5. Firsov A.A., Portnoy Y.A., Zinner S.H., PK/PD-based prediction of “anti-mutant” antibiotic exposures using in vitro dynamic models. In: Antimicrobial Resistance in the 21st Century. 2nd ed. (Editors: Fong, I.W., Shlaes, David, Drlica, Karl). Springer International Publishing. 2018. Р. 643-666. ISBN 978-3-319-78538-7. DOI: 10.1007/978-3-319-78538-7_21. Монография

  6. Alieva K.N., Strukova E.N., Golikova M.V., Portnoy Y.A., Zinner S.H., Firsov A.A. Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid. //J. Antibiot./ 2018. V. 71 № 5 P. 514-521. DOI: 10.1038/s41429-017-0016-9.

  7. Zinner S.H, Golikova M.V., Strukova E.N., Portnoy Y.A., Firsov A.A. Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: in vitro model studies with linezolid and gentamicin. // Int. J. Antimicrob. Agents./ 2018. V.52. №6. P.854-860. DOI:10.1016/j.ijantimicag.2018.09.005.

  8. Alieva K.N., Golikova M.V., Portnoy Y.A., Dovzhenko S.A., Kobrin M.B., Zinner S.H. Firsov A.A. Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitrodynamic model. // Journal of Chemotherapy./ 2018. V30. №6-8. Р. 364-370. DOI: 10.1080/1120009X.2018.1533267.

  9. Golikova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA. Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically-derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus. J Chemother. 2017. 29 (5): 267- 273. http://dx.doi.org/10.1080/1120009X.2017.1281093.
  10.     Strukova EN, Portnoy YA, Zinner SH, Firsov AA. Species differences in ciprofloxacin resistance among gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically? J Chemother. 2017. 29 6):351-357. http://dx.doi.org/10.1080/1120009X.2017. 1335980.
  11.     Firsov AA, Alieva KN, Strukova EN, Golikova MV, Portnoy YA, Dovzhenko SA, Kobrin MB, Romanov AV, Edelstein MV, Zinner SH. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. J Antimicrob Chemother. 2017. 72: 3100-3107. doi:10.1093/jac/dkx249.
  12.     Strukova E.N., Portnoy Y.A., Romanov A.V., Edelstein M.V., Zinner S.H., Firsov A.A. Сiprofloxacin resistance in Klebsiella pneumoniae: searching for the optimal predictor using in vitro dynamic models. Antimicrob Agents Chemother. 2016. V.60, Р. 1208-1215. doi: 10.1128/AAC.02334-15.
  13.     Strukova E.N., Portnoy Y.A., Zinner S.H., Firsov A.A. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentrations. J. Antimicrob Chemother. 2016. V.71, №3, Р.678-684. doi: 10.1093/jac/dkv387.
  14.     Firsov A.A., Golikova M.V., Strukova E.N., Portnoy Y.A., Dovzhenko S.A., Kobrin M.B., Zinner S.H. Pharmacokinetically based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin. Journal of Chemotherapy. 2016. Р.1-7. Doi: 10.1080/1120009X.2016.1245174.
  15.     Алиева К.Н., Струкова Е.Н., Голикова М.В., Портной Ю.А., Фирсов А.А. Зависимая от концентрации антибиотика селекция линезолидо-усточивых стафилокок-ков в динами-ческой системе in vitro. Антибиотики и химиотерапия, 2016, Т 61; № 9-10.
  16.     Shtyrlin N.V., Sapozhnikov S.V., Galiullin A.S., Kayumov A.R., Bondar O.V., Mirchink Е.P., Isakova Е.B., Firsov А.А., Balakin K.V., Shtyrlin G.Y. Synthesis and antibacterial activity of quaternary ammonium 4-deoxypyridoxine derivatives. BioMed Res Int. 2016. doi: 10.1155/2016/3864193.
  17.     Firsov A.A., Golikova M.V., Strukova E.N., Portnoy Y.A., Romanov A.V., Edelstein M.V., Zinner S.H. In vitro resistance studies with bacteria that exhibit low mutation frequencies: the prediction of “antimutant” linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphyloccocus aureus. Antimicrob Agents and Chemother, 2015, 59 (2), P. 1014-1019. doi: 10.1128/AAC.04214-14.
  18.     Strukova E.N., Portnoy Y.A., Zinner S.H., Firsov A.A. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentrations. J Antimicrob Chemother. 2015. doi: I 10.1093/jac/dkv 387.
  19.     Firsov A.A., Strukova E.N., Portnoy Y.A., Zinner S.H. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis versus susceptibility testing as endpoints of the mutant enrichment. Int J Antimicrob Agents 2015, V. 46 (3), P. 313-318. doi: 10.1016/j.ijantimicag.2015.06.007.
  20.     Голикова М.В., Струкова Е.Н., Портной Ю.А., Фирсов А.А. Прогнозирование антибиотикорезистентности бактерий методами фармакокинетико-фармакодинамического моделирования: альтернативные подходы к анализу экспериментальных данных. //Антибиотики и химиотерапия. 2015, т. 60, №9-10, с. 11-16.
  21.     AA Firsov, YA Portnoy, EN Strukova, DS Shlykova, SH Zinner. 2014. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. International Journal of Antimicrobial Agents, 44: 301-305. DOI information: 10.1016/j.ijantimicag.2014.06.013.
  22.     AA Firsov, EN Strukova, DS Shlykova, YA Portnoy, VK Kozyreva, MV Edelstein, SA Dovzhenko, MB Kobrin, SH Zinner. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob. Agents Chemother., 2013, 57(10): 4956-62. doi: 10.1128/AAC00578-13
  23.     SH Zinner, D Gilbert, K Greer, YA Portnoy, AA Firsov.. Сoncentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J. Antimicrob. Chemother., 2013, 68: 881–887. doi:10.1093/jac/dks463.
  24.     3. S. H. Zinner, D. Gilbert, K. Greer, Y. A. Portnoy and A. A. Firsov. Сoncentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J. Antimicrob. Chemother. 2012; doi: 10.1093/jac/dks463
  25.     2. A. A. Firsov, D. Gilbert, K. Greer, Y. A. Portnoy, S. H. Zinner. 2012. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob. Agents Chemother. 56:1223-1228
  26.     S. Zinner, D. Gilbert, K. Greer, Y. Portnoy, A. Firsov. Anti-mutant potentials of doripenem, imipenem and ciprofloxacin against Pseudomonas aeruginosa examined using an in vitro dynamic model. 2012. Clin Microb Infect, 18(Suppl. S3):440, abstr. 1610
  27.     Smirnova M.V., Stukova E.N., Portnoy Y.A., Dovzhenko S.A., Kobrin M.B., Zinner S.H., Firsov A.A. The antistaphylococcal pharmaco¬dynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model J. Chemother., 2011, Vol. 23, #3, p. 140-144
  28.     Струкова Е.Н., Смирнова М.В., Портной Ю.А., Фирсов А.А. Методические подходы к моделированию процессов развития антибиотикорезистентности in vitro. Клин. микробиол. антимикроб. терапия, 2010, .т. 12, №2 (Прилож. 1), с. 49
  29.     6. Zinner S., Gilbert D., Portnoy Y., Firsov A. Comparative Resistance studies with Pseudomonas aeruginosa exposed to doripenem (DOP) and imipenem (IMP) in an in vitro dynamic model. 48th Intersci. Conf. Antimicrob. Agents and Chemother. Abstracts, 2010, Abstr. O-74
  30.     Firsov A., Smirnova M., Strukova E., Portnoy Y., Zinner S. Staphylococcal resistance studies using susceptible organisms supplemented with their resistant mutants: combined treatment with linezolid (LZD) and gentamicin (GEN) simulated in an in vitro dynamic model. 48th Intersci. Conf. Antimicrob. Agents and Chemother Abstracts, 2010, Abstr. A1-006
  31.     Smirnova M., Strukova E., Portnoy Y., Zinner S., Firsov A. Amplification of Staphylococcus aureus mutants resistant to linezolid (LZD) and prediction of its antimutant concentrations using an in vitro dynamic model. 48th Intersci. Conf. Antimicrob. Agents and Chemother. Abstracts, 2010, Abstr. A1-005
  32.     Firsov A., Smirnova M., Strukova E., Portnoy Y., Zinner S. Bacterial resistance studies in an in vitro dynamic model: use of antibiotic-susceptible organisms supplemented with their resistant mutants. Clin. Microbiol. Infect. 2010, Vol. 16, Issue 2, Abstract P1601
  33.     Zinner S., Smirnova M., Strukova E., Portnoy Y., Firsov A. Rationale of combined antibiotic therapy derived from in vitro PK/PD studies: role of treatment duration simulated in a dynamic model. Clin. Microbiol. Infect. 2010, Vol. 16, Issue 2, Abstract P1600
  34.     Zinner S., Smirnova M., Strukova E., Firsov A. Evaluation of the pharmacodynamics of daptomycin (DAP)-rifampin (RIF) combinations with Staphylococcus aureus using various in vitro methods. Final Program and Abstracts of the 14th Int. Congress on Infectious Diseases (ICID), Miami, FL, March 9-12, 2010, Abstr. 49.007
  35.     Фирсов А.А., Портной Ю.А., Довженко С.А., Кобрин М.Б., Киселев А.В.Долгова Г.В.Померанцева Т.Я Фармакокинетические свойства кальциевой соли N-(5-оксиникотиноил)-l-глутаминовой кислоты при внутривенном введении крысам и кроликам: межвидовая экстраполяция Экспер. и Клин. Фармакол., 2010, т. 73, №12, с. 31-35
  36.     Smirnova M.V., Vostrov S. N.,Strukova E.N.,Dovzhenko S.A., Kobrin M.B. Portnoy,Y. A. Zinner S.H.,Firsov A.A. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models J. Antimicrob. Chemother. 2009, Vol. 64, p. 815-820
  37.     Струкова Е.Н., Смирнова М.В., Востров С.Н., Портной Ю.А.,Довженко С.А., Кобрин М.Б., Фирсов А.А.Антистафилококковые эффекты телаванцина и ванкомицина при моделировании их фармакокинетики in vitro Клин. Микробиол. Антимикроб. Химиотерапия , 2009, Т. 11, № 1, С. 56-65
  38.     Firsov, A. A., I. Y. Lubenko, S. N. Vostrov, Y. A. Portnoy, and Zinner, S. H. 2005.Anti-staphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven floroquinolones. Antimicrob Agents Chemother. 49:2642-2647
  39.     Firsov, A. A., I. V. Alferova, M. V. Smirnova, I. Y. Lubenko, Y. A. Portnoy, and Zinner, S. H. 2005. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 25:409-413
  40.     Firsov, A. A., I. V. Alferova, M. V. Smirnova, I. Y. Lubenko, Y. A. Portnoy, and Zinner, S. H. 2005. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 25:409-413
  41.     Фирсов, А.А., С.Н. Востров, И.Ю. Лубенко, Ю.А. Портной. 2004. Предотвращение селекции резистентных стафилококков в динамической системе in vitro, моделирующей фармакокинетику фторхинолонов. Клин Микробиол Антимикроб Химиотер. 6:252-259
  42.     Zinner, S. H., S. N. Vostrov, I. V. Alferova, I. Y. Lubenko, Y. A. Portnoy, and A. A. Firsov. 2004. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in-vitro dynamic model. Int J Antimicrob Agents. 24:173-177
  43.     Zinner, S. H., S. N. Vostrov, I. V. Alferova, I. Y. Lubenko, Y. A. Portnoy, and A. A. Firsov. 2004. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in-vitro dynamic model. Int J Antimicrob Agents. 24:173-177
  44.     Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, A. A. Arzamastsev, Y. A. Portnoy, and S. H. Zinner. 2004. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 54:178-186.
  45.     Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, Y. A. Portnoy, and S. H. Zinner. 2004. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. . Int J Antimicrob Agents. 23:451-456
  46.     Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, S. H. Zinner, and Y. A. Portnoy. 2004. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int J Antimicrob Agents. 23:60-66
  47.     Zinner, S. H., I. Y. Lubenko, D. Gilbert, K. Simmons, X. Zhao, K. Drlica, and A. A. Firsov. 2003. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob Chemother 52:616-622
  48.     Zinner, S. H., I. Y. Lubenko, D. Gilbert, K. Simmons, X. Zhao, K. Drlica, and A. A. Firsov. 2003. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J. Antimicrob Chemother. 52:616-622
  49.     Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother.47:1604-1613
  50.     Firsov, A. A., S. H. Zinner, I. Y. Lubenko, Y. A. Portnoy, and S. N. Vostrov. 2002. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of IE over other integral parameters. Chemotherapy. 48:275-279
  51.     Firsov, A. A., S. H. Zinner, I. Y. Lubenko, Y. A. Portnoy, and S. N. Vostrov. 2002. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of IE over other integral parameters. Chemotherapy. 48:275-279.
  52.     Firsov, A. A., S. H. Zinner, S. N. Vostrov, Y. A. Portnoy, and I. Y. Lubenko. 2002. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J. Antimicrob Chemother.50:533-539
  53.     Portnoy, Y. A., Vostrov, S. H., I. Y.Lubenko, S. N. Zinner, and A. A. Firsov. 2002. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilis influenzae and Moraxella catarrhalis in an in vitro dynamic model. Int J Antimicrob Agents. 20:201-205.
  54.     Lubenko, I. Y., S. N. Vostrov, Y. A. Portnoy, S. H. Zinner, and A. A. Firsov. 2002. Bacterial strain-independent AUC/MIC and strain-specific dose response relationships reflecting comparative fluoroquinolone pharmacodynamics in an in vitro dynamic model. Int J Antimicrob Agents. 20:44-49
  55.     Firsov, A. A., S. H. Zinner, S. N. Vostrov, O. V. Kononenko, Y. A. Portnoy, L. V. Shustova, and I. B. Kadenatsi. 2002. Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. J Antimicrob Chemother. 49:113-119
  56.     Zinner, S. H., S. N. Vostrov, I. Y. Lubenko, Y. A. Portnoy, G. Cornaglia, and A. A. Firsov. 2001. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn Microbiol Infect Dis. 40 (4):167-171
  57.     Zinner, S. H., A. A. Firsov, D. Gilbert, K. Simmons, and I. Y. Lubenko. 2001. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: Prediction of equiefficient doses. J Antimicrob Chemother. 48:821-826
  58.     Firsov, A. A., and S. H. Zinner. 2001. Use of modeling techniques to aid in antibiotic selection. Curr Infect Dis Rep. 3:35-43
  59.     Firsov, A. A., I. Y. Lubenko, Y. A. Portnoy, S. H. Zinner, and S. N. Vostrov. 2001. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: Gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother. 45:927-931.

Перейти к "Лаборатория фармакокинетики и фармакодинамики "